$54.73
0.510.94%
al cierre: -
$54.73
N/A
After hour: Nov 14, 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
BioMarin Pharmaceutical Inc tiene un precio objetivo de consenso de $92.79 basado en las calificaciones de 30 analistas. El máximo es $140, emitido por Truist Securities el septiembre 25, 2023. El mínimo es $55, emitido por HC Wainwright & Co. el octubre 27, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por Stifel, Bernstein y Truist Securities el noviembre 6, 2025, noviembre 3, 2025 y octubre 28, 2025, respectivamente. Con un precio objetivo promedio de $76.33 entre Stifel, Bernstein y Truist Securities, hay una 39.47% upside implícita para BioMarin Pharmaceutical Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Stifel
Bernstein
Truist Securities
Wells Fargo
Barclays
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para BioMarin Pharmaceutical
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | 11.46% | Stifel | $73 → $61 | Downgrade | Buy → Hold | |||
11/03/2025 | 60.79% | Bernstein | $95 → $88 | Maintains | Outperform | |||
10/28/2025 | 46.17% | Truist Securities | $90 → $80 | Maintains | Buy | |||
10/28/2025 | 27.9% | Wells Fargo | $90 → $70 | Maintains | Overweight | |||
10/28/2025 | 33.38% | Stifel | $91 → $73 | Maintains | Buy | |||
10/28/2025 | 46.17% | Barclays | $86 → $80 | Maintains | Overweight | |||
10/28/2025 | 79.06% | Morgan Stanley | $104 → $98 | Maintains | Overweight | |||
10/27/2025 | 0.49% | HC Wainwright & Co. | $60 → $55 | Maintains | Neutral | |||
10/09/2025 | 117.43% | JP Morgan | $116 → $119 | Maintains | Overweight | |||
09/08/2025 | 9.63% | HC Wainwright & Co. | → $60 | Initiates | → Neutral | |||
08/06/2025 | 93.68% | Guggenheim | $101 → $106 | Maintains | Buy | |||
08/05/2025 | 108.3% | UBS | $113 → $114 | Maintains | Buy | |||
07/22/2025 | 75.41% | Morgan Stanley | $97 → $96 | Maintains | Overweight | |||
07/14/2025 | 106.47% | JP Morgan | $108 → $113 | Maintains | Overweight | |||
05/05/2025 | 90.02% | Goldman Sachs | $124 → $104 | Maintains | Buy | |||
05/02/2025 | 42.52% | Citigroup | $82 → $78 | Maintains | Neutral | |||
02/24/2025 | 79.06% | Oppenheimer | → $98 | Upgrade | Perform → Outperform | |||
02/20/2025 | 46.17% | Scotiabank | $78 → $80 | Maintains | Sector Perform | |||
02/20/2025 | 49.83% | Citigroup | $81 → $82 | Maintains | Neutral | |||
02/20/2025 | 27.9% | RBC Capital | $70 → $70 | Reiterates | Sector Perform → Sector Perform | |||
02/20/2025 | 64.44% | Cantor Fitzgerald | $90 → $90 | Reiterates | Overweight → Overweight | |||
02/20/2025 | 106.47% | UBS | $109 → $113 | Maintains | Buy | |||
02/20/2025 | 130.22% | Piper Sandler | $122 → $126 | Maintains | Overweight | |||
02/20/2025 | 88.2% | B of A Securities | $99 → $103 | Maintains | Buy | |||
12/12/2024 | 64.44% | Cantor Fitzgerald | $90 → $90 | Reiterates | Overweight → Overweight | |||
11/15/2024 | 73.58% | Wolfe Research | → $95 | Initiates | → Outperform | |||
10/30/2024 | 48% | Citigroup | $93 → $81 | Maintains | Neutral | |||
10/30/2024 | 53.48% | Canaccord Genuity | $93 → $84 | Maintains | Hold | |||
10/30/2024 | 64.44% | Cantor Fitzgerald | $110 → $90 | Maintains | Overweight | |||
10/30/2024 | 99.16% | JP Morgan | $110 → $109 | Maintains | Overweight | |||
10/30/2024 | 46.17% | RBC Capital | $80 → $80 | Reiterates | Sector Perform → Sector Perform | |||
10/30/2024 | 91.85% | Evercore ISI Group | $115 → $105 | Maintains | Outperform | |||
10/30/2024 | 93.68% | UBS | $104 → $106 | Maintains | Buy | |||
10/30/2024 | 18.76% | Baird | $72 → $65 | Maintains | Neutral | |||
10/30/2024 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
10/10/2024 | 44.34% | Raymond James | → $79 | Reinstates | → Outperform | |||
10/04/2024 | 46.17% | RBC Capital | $85 → $80 | Maintains | Sector Perform | |||
10/04/2024 | 57.14% | Barclays | $110 → $86 | Maintains | Overweight | |||
09/17/2024 | 42.52% | Scotiabank | $95 → $78 | Maintains | Sector Perform | |||
09/17/2024 | 64.44% | Truist Securities | $118 → $90 | Maintains | Buy | |||
09/17/2024 | 64.44% | Wells Fargo | $115 → $90 | Maintains | Overweight | |||
09/17/2024 | 55.31% | RBC Capital | $100 → $85 | Maintains | Sector Perform | |||
09/17/2024 | 110.12% | B of A Securities | $130 → $115 | Maintains | Buy | |||
09/17/2024 | 58.96% | Stifel | $115 → $87 | Maintains | Buy | |||
09/17/2024 | 64.44% | Bernstein | $116 → $90 | Maintains | Outperform | |||
09/13/2024 | 69.93% | Canaccord Genuity | $93 → $93 | Maintains | Hold | |||
09/09/2024 | 100.99% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
09/05/2024 | 119.26% | JP Morgan | $111 → $120 | Maintains | Overweight | |||
09/05/2024 | 82.72% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
09/05/2024 | 73.58% | Scotiabank | $86 → $95 | Maintains | Sector Perform | |||
09/05/2024 | 115.6% | Truist Securities | $140 → $118 | Maintains | Buy | |||
09/05/2024 | 122.91% | Piper Sandler | $107 → $122 | Maintains | Overweight | |||
08/27/2024 | 95.51% | Piper Sandler | $107 → $107 | Maintains | Overweight | |||
08/21/2024 | 110.12% | Stifel | $112 → $115 | Maintains | Buy | |||
08/20/2024 | 100.99% | Bernstein | $94 → $110 | Upgrade | Market Perform → Outperform | |||
08/06/2024 | 119.26% | TD Cowen | $125 → $120 | Maintains | Buy | |||
08/06/2024 | 57.14% | Scotiabank | $85 → $86 | Maintains | Sector Perform | |||
08/06/2024 | 104.64% | Stifel | $108 → $112 | Maintains | Buy | |||
08/06/2024 | 82.72% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
08/06/2024 | 100.99% | Barclays | $111 → $110 | Maintains | Overweight | |||
08/06/2024 | 110.12% | Evercore ISI Group | $113 → $115 | Maintains | Outperform | |||
08/05/2024 | 100.99% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
07/25/2024 | 62.62% | Canaccord Genuity | $89 → $89 | Maintains | Hold | |||
07/22/2024 | 100.99% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
06/27/2024 | 110.12% | Wells Fargo | $110 → $115 | Maintains | Overweight | |||
05/17/2024 | 31.55% | Baird | $104 → $72 | Downgrade | Outperform → Neutral | |||
05/14/2024 | 106.47% | Evercore ISI Group | → $113 | Initiates | → Outperform | |||
04/26/2024 | 104.64% | Morgan Stanley | $115 → $112 | Maintains | Overweight | |||
04/26/2024 | 62.62% | Canaccord Genuity | $91 → $89 | Maintains | Hold | |||
04/25/2024 | 100.99% | Cantor Fitzgerald | $110 → $110 | Reiterates | Overweight → Overweight | |||
04/25/2024 | 66.27% | Citigroup | $94 → $91 | Maintains | Neutral | |||
04/25/2024 | 55.31% | Scotiabank | $83 → $85 | Maintains | Sector Perform | |||
04/25/2024 | 100.99% | Wells Fargo | $100 → $110 | Maintains | Overweight | |||
02/29/2024 | 66.27% | Canaccord Genuity | → $91 | Reiterates | Hold → Hold | |||
02/23/2024 | 82.72% | Cantor Fitzgerald | $100 → $100 | Reiterates | Overweight → Overweight | |||
02/23/2024 | 82.72% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
02/23/2024 | 95.51% | Piper Sandler | $115 → $107 | Maintains | Overweight | |||
01/30/2024 | 90.02% | Baird | $127 → $104 | Maintains | Outperform | |||
12/21/2023 | 84.54% | Stifel | $101 → $101 | Reiterates | Buy → Buy | |||
11/07/2023 | 82.72% | RBC Capital | $100 → $100 | Reiterates | Sector Perform → Sector Perform | |||
11/03/2023 | 82.72% | BMO Capital | $102 → $100 | Maintains | Outperform | |||
11/02/2023 | 110.12% | Piper Sandler | $125 → $115 | Maintains | Overweight | |||
11/02/2023 | 113.78% | Morgan Stanley | $125 → $117 | Maintains | Overweight | |||
11/02/2023 | 102.81% | Barclays | $125 → $111 | Maintains | Overweight | |||
11/02/2023 | 82.72% | Cantor Fitzgerald | $120 → $100 | Maintains | Overweight | |||
11/01/2023 | 84.54% | Stifel | $108 → $101 | Maintains | Buy | |||
10/23/2023 | 49.83% | Bernstein | → $82 | Upgrade | Underperform → Market Perform | |||
10/16/2023 | 119.26% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
09/28/2023 | — | Raymond James | — | Initiates | → Market Perform | |||
09/25/2023 | 155.8% | Truist Securities | → $140 | Reiterates | Buy → Buy | |||
09/18/2023 | 119.26% | UBS | → $120 | Initiates | → Buy | |||
09/15/2023 | 155.8% | Truist Securities | → $140 | Reiterates | Buy → Buy | |||
09/14/2023 | 119.26% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
09/13/2023 | 100.99% | Guggenheim | → $110 | Reiterates | Buy → Buy | |||
09/13/2023 | 82.72% | RBC Capital | → $100 | Reiterates | Sector Perform → Sector Perform | |||
09/13/2023 | 119.26% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight | |||
08/01/2023 | 128.39% | Morgan Stanley | $129 → $125 | Maintains | Overweight | |||
08/01/2023 | 97.33% | Stifel | $118 → $108 | Maintains | Buy | |||
08/01/2023 | 27.9% | Wedbush | $73 → $70 | Maintains | Neutral | |||
08/01/2023 | 119.26% | Cantor Fitzgerald | → $120 | Reiterates | Overweight → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de BioMarin Pharmaceutical (BMRN)?
El último precio objetivo de BioMarin Pharmaceutical (NASDAQ:BMRN) fue comunicado por Stifel el noviembre 6, 2025. La firma de analistas fijó un precio objetivo para $61.00 que espera BMRN a rise dentro de 12 meses (un posible 11.46% upside). 25 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre BioMarin Pharmaceutical (BMRN)?
La última calificación de analistas para BioMarin Pharmaceutical (NASDAQ:BMRN) fue proporcionada por Stifel, y BioMarin Pharmaceutical rebajado su hold calificación.
¿Cuándo se produjo la última revisión al alza de BioMarin Pharmaceutical (BMRN)?
La última revisión al alza de BioMarin Pharmaceutical Inc se produjo en febrero 24, 2025, cuando Oppenheimer elevó su precio objetivo a $98. Oppenheimer anteriormente tenía a perform para BioMarin Pharmaceutical Inc.
¿Cuándo fue la última revisión a la baja de BioMarin Pharmaceutical (BMRN)?
La última revisión a la baja de BioMarin Pharmaceutical Inc se produjo en noviembre 6, 2025, cuando Stifel cambió su precio objetivo de $73 a $61 para BioMarin Pharmaceutical Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para BioMarin Pharmaceutical (BMRN)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de BioMarin Pharmaceutical, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de BioMarin Pharmaceutical se registró el noviembre 6, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 6, 2026.
¿Es correcta la calificación de los analistas sobre BioMarin Pharmaceutical (BMRN)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de BioMarin Pharmaceutical (BMRN) fue un rebajado con un precio objetivo de $73.00 a $61.00. El precio actual al que cotiza BioMarin Pharmaceutical (BMRN) es de $54.73, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.